- Home
- RCUS vs OLN Comparison
RCUS vs OLN Comparison
Compare RCUS & OLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCUS | OLN |
|---|---|---|
| Founded | 2015 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.5B |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RCUS | OLN |
|---|---|---|
| Price | $27.27 | $22.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 13 |
| Target Price | ★ $31.90 | $25.23 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.92% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $247,000,000.00 | ★ $6,780,800,000.00 |
| Revenue This Year | N/A | $2.57 |
| Revenue Next Year | $45.62 | $3.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.68 |
| 52 Week Low | $8.84 | $18.08 |
| 52 Week High | $31.74 | $30.46 |
Technical Indicators
Market Signals| Indicator | RCUS | OLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 48.69 |
| Support Level | $25.68 | $19.37 |
| Resistance Level | $28.72 | $24.83 |
| Average True Range (ATR) | 1.34 | 0.95 |
| MACD | -0.29 | 0.26 |
| Stochastic Oscillator | 29.85 | 46.54 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
About OLN Olin Corporation
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.